Liisa Bayko
Stock Analyst at Evercore ISI Group
(3.67)
# 786
Out of 5,055 analysts
81
Total ratings
58.21%
Success rate
28.08%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Liisa Bayko
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ENTA Enanta Pharmaceuticals | Maintains: Outperform | $20 → $12 | $12.05 | -0.41% | 5 | Sep 15, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Outperform | $510 → $475 | $437.15 | +8.66% | 19 | Sep 11, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $280 → $515 | $449.16 | +14.67% | 2 | Sep 11, 2025 | |
| SVRA Savara | Maintains: In-Line | $3 → $2 | $4.30 | -53.49% | 5 | May 28, 2025 | |
| CRSP CRISPR Therapeutics AG | Upgrades: Outperform | $60 → $99 | $52.53 | +88.46% | 2 | Feb 14, 2025 | |
| TVTX Travere Therapeutics | Maintains: Outperform | $33 → $45 | $34.50 | +30.43% | 5 | Feb 12, 2025 | |
| BCRX BioCryst Pharmaceuticals | Maintains: Outperform | $10 → $12 | $7.08 | +69.49% | 5 | Jan 13, 2025 | |
| EDIT Editas Medicine | Maintains: Outperform | $7 → $5 | $2.60 | +92.31% | 5 | Dec 16, 2024 | |
| KNSA Kiniksa Pharmaceuticals International, | Maintains: Outperform | $30 → $35 | $40.37 | -13.30% | 4 | Oct 30, 2024 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Outperform | $405 → $360 | $529.21 | -31.97% | 9 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $7 → $2 | $1.14 | +75.44% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $38 | $54.25 | -29.95% | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $60 → $80 | $33.08 | +141.84% | 8 | Jun 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $18 | $12.57 | +43.20% | 1 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $25 | $4.17 | +499.52% | 1 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $35 | $5.53 | +532.91% | 1 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $24 | $28.35 | -15.34% | 1 | Jun 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $30 | $17.37 | +72.71% | 1 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Outperform | $10 | $4.52 | +121.24% | 1 | Feb 5, 2020 |
Enanta Pharmaceuticals
Sep 15, 2025
Maintains: Outperform
Price Target: $20 → $12
Current: $12.05
Upside: -0.41%
Vertex Pharmaceuticals
Sep 11, 2025
Maintains: Outperform
Price Target: $510 → $475
Current: $437.15
Upside: +8.66%
Alnylam Pharmaceuticals
Sep 11, 2025
Maintains: Outperform
Price Target: $280 → $515
Current: $449.16
Upside: +14.67%
Savara
May 28, 2025
Maintains: In-Line
Price Target: $3 → $2
Current: $4.30
Upside: -53.49%
CRISPR Therapeutics AG
Feb 14, 2025
Upgrades: Outperform
Price Target: $60 → $99
Current: $52.53
Upside: +88.46%
Travere Therapeutics
Feb 12, 2025
Maintains: Outperform
Price Target: $33 → $45
Current: $34.50
Upside: +30.43%
BioCryst Pharmaceuticals
Jan 13, 2025
Maintains: Outperform
Price Target: $10 → $12
Current: $7.08
Upside: +69.49%
Editas Medicine
Dec 16, 2024
Maintains: Outperform
Price Target: $7 → $5
Current: $2.60
Upside: +92.31%
Kiniksa Pharmaceuticals International,
Oct 30, 2024
Maintains: Outperform
Price Target: $30 → $35
Current: $40.37
Upside: -13.30%
Madrigal Pharmaceuticals
Aug 8, 2024
Maintains: Outperform
Price Target: $405 → $360
Current: $529.21
Upside: -31.97%
May 16, 2024
Maintains: In-Line
Price Target: $7 → $2
Current: $1.14
Upside: +75.44%
May 15, 2024
Maintains: Outperform
Price Target: $50 → $38
Current: $54.25
Upside: -29.95%
Jun 6, 2023
Upgrades: Outperform
Price Target: $60 → $80
Current: $33.08
Upside: +141.84%
Mar 28, 2023
Initiates: Outperform
Price Target: $18
Current: $12.57
Upside: +43.20%
Jan 18, 2023
Maintains: Outperform
Price Target: $14 → $25
Current: $4.17
Upside: +499.52%
Nov 23, 2021
Initiates: Outperform
Price Target: $35
Current: $5.53
Upside: +532.91%
Jun 8, 2021
Initiates: Outperform
Price Target: $24
Current: $28.35
Upside: -15.34%
Nov 24, 2020
Reinstates: Outperform
Price Target: $30
Current: $17.37
Upside: +72.71%
Feb 5, 2020
Upgrades: Market Outperform
Price Target: $10
Current: $4.52
Upside: +121.24%